Warfarin sensitivity: Be aware of genetic influence

Age and Ageing

Volumn 32, Issue 2, 2003, Pages 226-227

  Khan, Tayyaba ^a   Kamali, Farhad ^a   Daly, Ann ^a   King, Barry ^a   Wynne, Hilary A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anticoagulation; Cytochrome P450 2C9; Genetic polymorphism; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; VITAMIN K GROUP; WARFARIN;

AGED; ALLELE; ARTICLE; BLEEDING; CASE REPORT; CLINICAL FEATURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEREDITY; HUMAN; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; THROMBOPHLEBITIS; WARFARIN;

EID: 12244303655     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/32.2.226     Document Type: Article

References (6)

1. Wynne HA, Kamali F, Edwards C, Long A, Kelly P. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996; 25: 429-43.
2. Routledge PA, Chapman PH, Davies DM, Rawlins MD. Factors affecting warfarin requirements. A prospective population study. Eur J Clin Pharmacol 1979; 15: 319-22.
3. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, Kamali F. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40: 203-7.
4. Rettie AE, Korezekwa KR, Kunxe KL et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S) warfarin drug interactions. Chem Res Toxicol 1992; 5: 54-9.
5. Rettie AE, Wienkers LC, Gonzlez FJ, Trager WF, Korezekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allele variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
6. Linder WM. Genetic mechanisms for hypersensitivity and resistance to the anticoagulant warfarin. Clin Chim Acta 2001; 308: 9-15.